Findings of two large phase III clinical trials first presented in 2020 showed a new HIV prevention injection to be highly effective. Yet, experts expect that the injection will only reach clinics in late 2022 or early 2023. If the rhetoric about bringing the urgency of COVID-19 to HIV is to mean anything, these timelines should be made shorter.
From March to July this year, the Gauteng Department of Health recorded 57 848 TB tests – a decrease of about 30 000 tests compared to the same period last year. The province performed better with HIV testing, although the HIV response has faltered in other areas. Melissa Javan makes sense of the province’s numbers and speaks to activists and community health workers about the impact of lockdown on their services and plans to get things back on track.
While South Africa is doing well on some of the UNAIDS HIV targets for 2020, one target we are set to miss is ensuring that 90% of people diagnosed with HIV are on antiretroviral therapy. Partly in response to this problem, the ‘Welcome back’ campaign started by Doctors without Borders aims to make it easier for people who have stopped taking treatment to restart. Tiyese Jeranji reports.
The U=U campaign is based on a simple message – an undetectable viral load in people living with HIV equals an untransmissible virus. The U=U campaign, argues Mandisa Dukashe, has the power to motivate people living with HIV to adhere to ARVs, achieve viral suppression, and subsequently lead long and healthy lives while preventing HIV transmission to sexual partners and their babies.